MedTrace Logo

Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)

NCT00966030 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-07-07

No results posted yet for this study

Summary

This study will demonstrate the definitive bioequivalence of a solid dose formulation of MK0974 to the liquid filled capsule formulation of MK0974.

Conditions

Interventions

DRUG

MK0974 tablet

MK0974 280 mg tablet in one of two treatment periods

DRUG

Comparator: MK0974 liquid filled capsule

MK0974 300 mg liquid filled capsule in one of two treatment periods

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966030 on ClinicalTrials.gov